Anzahl der Einträge: 6.
Weller, Johannes ,
Schäfer, Niklas,
Schaub, Christina,
Potthoff, Anna-Laura,
Steinbach, Joachim P.,
Schlegel, Uwe,
Sabel, Michael ,
Hau, Peter ,
Seidel, Clemens,
Krex, Dietmar,
Goldbrunner, Roland,
Pietsch, Torsten,
Tzaridis, Theophilos,
Zeyen, Thomas,
Borger, Valeri,
Güresir, Erdem,
Vatter, Hartmut,
Herrlinger, Ulrich und
Schneider, Matthias
(2022)
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Journal of Neuro-Oncology 159 (1), S. 95-101.
Zeyen, Thomas,
Potthoff, Anna-Laura,
Nemeth, Robert,
Heiland, Dieter H.,
Burger, Michael C.,
Steinbach, Joachim P.,
Hau, Peter,
Tabatabai, Ghazaleh,
Glas, Martin,
Schlegel, Uwe,
Grauer, Oliver,
Krex, Dietmar,
Schnell, Oliver,
Goldbrunner, Roland,
Sabel, Michael ,
Thon, Niklas,
Delev, Daniel,
Clusmann, Hans,
Seidel, Clemens,
Güresir, Erdem,
Schmid, Matthias ,
Schuss, Patrick ,
Giordano, Frank A.,
Radbruch, Alexander,
Becker, Albert,
Weller, Johannes,
Schaub, Christina,
Vatter, Hartmut,
Schilling, Judith,
Winkler, Frank ,
Herrlinger, Ulrich und
Schneider, Matthias
(2022)
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial.
Trials 23 (1).
Volltext nicht vorhanden.
Tzaridis, Theophilos ,
Schäfer, Niklas,
Weller, Johannes,
Steinbach, Joachim‐Peter,
Schlegel, Uwe,
Seidel, Sabine,
Sabel, Michael,
Hau, Peter,
Seidel, Clemens,
Krex, Dietmar,
Goldbrunner, Roland,
Tonn, Jörg‐Christian,
Grauer, Oliver,
Kebir, Sied,
Schneider, Matthias,
Schaub, Christina,
Vatter, Hartmut,
Coch, Christoph,
Glas, Martin,
Fimmers, Rolf,
Pietsch, Torsten,
Reifenberger, Guido,
Herrlinger, Ulrich und
Felsberg, Jörg
(2021)
MGMT promoter methylation analysis for allocating combined CCNU / TMZ chemotherapy: Lessons learned from the CeTeG / NOA ‐09 trial.
International Journal of Cancer 148 (7), S. 1695-1707.
Volltext nicht vorhanden.
Kebir, Sied,
Schaub, Christina,
Junold, Nina,
Hattingen, Elke ,
Schäfer, Niklas,
Steinbach, Joachim P.,
Weyerbrock, Astrid,
Hau, Peter,
Goldbrunner, Roland,
Galldiks, Norbert ,
Weller, Johannes ,
Mack, Frederic,
Tzaridis, Theophilos,
Bähr, Oliver,
Seidel, Clemens,
Schlegel, Uwe,
Schmidt-Graf, Friederike,
Rohde, Veit,
Borchers, Christian,
Tabatabai, Ghazaleh ,
Hänel, Mathias,
Sabel, Michael,
Gerlach, Rüdiger,
Krex, Dietmar,
Belka, Claus,
Vatter, Hartmut,
Proescholdt, Martin,
Glas, Martin und
Herrlinger, Ulrich
(2019)
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Journal of Neuro-Oncology 144 (3), S. 501-509.
Volltext nicht vorhanden.
Weller, Johannes ,
Tzaridis, Theophilos,
Mack, Frederic,
Steinbach, Joachim Peter,
Schlegel, Uwe,
Hau, Peter,
Krex, Dietmar,
Grauer, Oliver,
Goldbrunner, Roland,
Bähr, Oliver,
Uhl, Martin,
Seidel, Clemens,
Tabatabai, Ghazaleh ,
Brehmer, Stefanie,
Bullinger, Lars,
Galldiks, Norbert ,
Schaub, Christina,
Kebir, Sied,
Stummer, Walter,
Simon, Matthias,
Fimmers, Rolf,
Coch, Christoph,
Glas, Martin,
Herrlinger, Ulrich und
Schäfer, Niklas
(2019)
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
The Lancet Oncology 20 (10), S. 1444-1453.
Volltext nicht vorhanden.
Herrlinger, Ulrich,
Tzaridis, Theophilos,
Mack, Frederic,
Steinbach, Joachim Peter,
Schlegel, Uwe,
Sabel, Michael,
Hau, Peter ,
Kortmann, Rolf-Dieter,
Krex, Dietmar,
Grauer, Oliver,
Goldbrunner, Roland,
Schnell, Oliver,
Bähr, Oliver,
Uhl, Martin,
Seidel, Clemens,
Tabatabai, Ghazaleh ,
Kowalski, Thomas,
Ringel, Florian,
Schmidt-Graf, Friederike,
Suchorska, Bogdana,
Brehmer, Stefanie,
Weyerbrock, Astrid,
Renovanz, Miriam,
Bullinger, Lars,
Galldiks, Norbert ,
Vajkoczy, Peter,
Misch, Martin,
Vatter, Hartmut,
Stuplich, Moritz,
Schäfer, Niklas,
Kebir, Sied,
Weller, Johannes ,
Schaub, Christina,
Stummer, Walter,
Tonn, Jörg-Christian,
Simon, Matthias,
Keil, Vera C.,
Nelles, Michael,
Urbach, Horst,
Coenen, Martin,
Wick, Wolfgang ,
Weller, Michael ,
Fimmers, Rolf,
Schmid, Matthias ,
Hattingen, Elke ,
Pietsch, Torsten,
Coch, Christoph und
Glas, Martin
(2019)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial.
The Lancet 393 (10172), S. 678-688.
Volltext nicht vorhanden.
Diese Liste wurde erzeugt am Mon May 6 01:31:01 2024 CEST.